cyproheptadine has been researched along with Adenoma in 19 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The therapeutic efficacy of the combination of cyproheptadine and bromocriptine was studied in 15 patients with active acromegaly showing incomplete GH suppression in response to bromocriptine therapy alone." | 7.67 | The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly. ( Hanew, K; Ishii, K; Saitoh, T; Sasaki, A; Saso, S; Sato, S; Shimizu, Y; Sugawara, A; Tazawa, S; Yoshinaga, K, 1989) |
| "A 44-year-old female with Cushing's disease associated with a pituitary macroadenoma was treated with cyproheptadine, 24 mg per day, after partial surgical resection of the tumor." | 7.67 | Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma. ( Ooi, TC; Twum-Barima, Y, 1987) |
| "In an attempt to delineate the mechanism and the site of action of cyproheptadine and dopaminergic agonists as well as hormones including thyrotropin-releasing hormone (TRH) and hydrocortisone, the effects of these substances on ACTH secretion from corticotroph adenoma cells in culture were examined." | 7.66 | Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. ( Ishibashi, M; Yamaji, T, 1981) |
| "To study the role of serotonin in regulating the release of aldosterone, we gave single, oral doses of cyproheptadine, an antiserotoninergic agent, to five normal volunteers with high aldosterone levels secondary to sodium deprivation and to 14 patients with aldosteronism (six with idiopathic aldosteronism due to bilateral adrenal hyperplasia and eight with adrenal adenoma)." | 7.66 | Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. ( Gniadek, TC; Grekin, RJ; Gross, MD; Villareal, JZ, 1981) |
| "The therapeutic efficacy of the combination of cyproheptadine and bromocriptine was studied in 15 patients with active acromegaly showing incomplete GH suppression in response to bromocriptine therapy alone." | 3.67 | The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly. ( Hanew, K; Ishii, K; Saitoh, T; Sasaki, A; Saso, S; Sato, S; Shimizu, Y; Sugawara, A; Tazawa, S; Yoshinaga, K, 1989) |
| "A 44-year-old female with Cushing's disease associated with a pituitary macroadenoma was treated with cyproheptadine, 24 mg per day, after partial surgical resection of the tumor." | 3.67 | Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma. ( Ooi, TC; Twum-Barima, Y, 1987) |
| "In an attempt to delineate the mechanism and the site of action of cyproheptadine and dopaminergic agonists as well as hormones including thyrotropin-releasing hormone (TRH) and hydrocortisone, the effects of these substances on ACTH secretion from corticotroph adenoma cells in culture were examined." | 3.66 | Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. ( Ishibashi, M; Yamaji, T, 1981) |
| "Direct effects of cyproheptadine, reserpine, synthetic ovine corticotropin-releasing factor (CRF), dexamethasone, and lysine-8-vasopressin (LVP) on the secretion of immunoreactive ACTH and beta-endorphin from the adenoma and the nonadenomatous tissue of patients with Cushing's disease were examined using a superfusion system." | 3.66 | Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. ( Demura, H; Mouri, T; Sasaki, A; Shibasaki, T; Shizume, K; Suda, T; Tozawa, F, 1983) |
| "To study the role of serotonin in regulating the release of aldosterone, we gave single, oral doses of cyproheptadine, an antiserotoninergic agent, to five normal volunteers with high aldosterone levels secondary to sodium deprivation and to 14 patients with aldosteronism (six with idiopathic aldosteronism due to bilateral adrenal hyperplasia and eight with adrenal adenoma)." | 3.66 | Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. ( Gniadek, TC; Grekin, RJ; Gross, MD; Villareal, JZ, 1981) |
| "When cabergoline was reintroduced there was a clinical improvement and normalization of ACTH plasma levels (64 pg/ml)." | 1.32 | Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. ( Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A, 2004) |
| " Remission was achieved with cyproheptadine up to a dosage of 24 mg/day." | 1.29 | Cyproheptadine treatment in Cushing's disease. ( Alagöl, F; Azizlerli, H; Berker, F; Sandalci, O; Tanakol, R; Terzioğlu, T, 1996) |
| "189 patients with secretory pituitary adenomas underwent medical therapy for the hypersecretory state." | 1.27 | The medical treatment of the hypersecreting pituitary gland. ( Corenblum, B, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (73.68) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casulari, LA | 1 |
| Naves, LA | 1 |
| Mello, PA | 1 |
| Pereira Neto, A | 1 |
| Papadia, C | 1 |
| Krieger, DT | 2 |
| Calderón Gualda, MD | 1 |
| Martínez de Osaba, MJ | 1 |
| Palacín, A | 1 |
| Vilardell, E | 1 |
| Ishibashi, M | 1 |
| Yamaji, T | 2 |
| Lankford, HV | 1 |
| Tucker, HS | 1 |
| Blackard, WG | 1 |
| Suda, T | 1 |
| Tozawa, F | 1 |
| Mouri, T | 1 |
| Sasaki, A | 2 |
| Shibasaki, T | 1 |
| Demura, H | 1 |
| Shizume, K | 1 |
| Gross, MD | 1 |
| Grekin, RJ | 1 |
| Gniadek, TC | 1 |
| Villareal, JZ | 1 |
| van Waveren Hogervorst, CO | 1 |
| Koppeschaar, HP | 1 |
| Zelissen, PM | 1 |
| Lips, CJ | 1 |
| Garcia, BM | 1 |
| Tanakol, R | 1 |
| Alagöl, F | 1 |
| Azizlerli, H | 1 |
| Sandalci, O | 1 |
| Terzioğlu, T | 1 |
| Berker, F | 1 |
| Gerasimov, G | 1 |
| Chernova, T | 1 |
| Goncharov, N | 1 |
| Fanghanel, G | 1 |
| Larraza, O | 1 |
| Villalobos, M | 1 |
| Fanghanel, L | 1 |
| Velasco, M | 1 |
| Velasco, F | 1 |
| Hanew, K | 1 |
| Sugawara, A | 1 |
| Shimizu, Y | 1 |
| Sato, S | 1 |
| Tazawa, S | 1 |
| Ishii, K | 1 |
| Saitoh, T | 1 |
| Saso, S | 1 |
| Yoshinaga, K | 1 |
| Corenblum, B | 1 |
| Yoshida, H | 1 |
| Takeda, F | 1 |
| Kinouchi, T | 1 |
| Shimizu, N | 1 |
| Ooi, TC | 1 |
| Twum-Barima, Y | 1 |
| Burch, WM | 1 |
3 reviews available for cyproheptadine and Adenoma
| Article | Year |
|---|---|
Physiopathology of Cushing's disease.
Topics: Adenoma; Biomechanical Phenomena; Bromocriptine; Circadian Rhythm; Cushing Syndrome; Cyproheptadine; | 1983 |
[Drug and radiotherapy of pituitary tumors].
Topics: Acromegaly; Adenoma; Adrenocorticotropic Hormone; Bromocriptine; Cushing Syndrome; Cyproheptadine; G | 1986 |
Cushing's disease. A review.
Topics: Adenoma; Adolescent; Adrenalectomy; Adult; Animals; Bromocriptine; Child; Combined Modality Therapy; | 1985 |
16 other studies available for cyproheptadine and Adenoma
| Article | Year |
|---|---|
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadi | 2004 |
[An ACTH-secreting pituitary macroadenoma: inhibitory effect of cyproheptadine and somatostatin].
Topics: Adenoma; Cushing Syndrome; Cyproheptadine; Female; Humans; Middle Aged; Pituitary Neoplasms; Somatos | 1984 |
Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.
Topics: Adenoma; Adrenocorticotropic Hormone; Cells, Cultured; Cushing Syndrome; Cyproheptadine; Dopamine; H | 1981 |
A cyproheptadine-reversible defect in ACTH control persisting after removal of the pituitary tumor in Cushing's disease.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Cushing Syndrome; Cyproheptadine; Feedback; Hum | 1981 |
Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease.
Topics: Adenoma; Adrenocorticotropic Hormone; beta-Endorphin; Corticotropin-Releasing Hormone; Cushing Syndr | 1983 |
Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Cyproheptadine; Depression, Chemical; Diet, So | 1981 |
[Medical treatment of functioning pituitary adenomas (author's transl)].
Topics: Acromegaly; Adenoma; Adult; Bromocriptine; Cyproheptadine; Dopamine; Female; Humans; Hypotension; Ma | 1981 |
Cyproheptadine in idiopathic aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Cyproheptadine; Dexamethasone; Drug Synergism; Humans | 1981 |
Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment.
Topics: Adenoma; Adult; Cushing Syndrome; Cyproheptadine; Female; Humans; Hydrocortisone; Male; Middle Aged; | 1996 |
Cyproheptadine treatment in Cushing's disease.
Topics: Adenoma; Adolescent; Cushing Syndrome; Cyproheptadine; Female; Follow-Up Studies; Humans; Pituitary | 1996 |
The central nervous system and Cushing's disease.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Central Nervous Syste | 1978 |
Monoamine regulation of prolactin and TSH secretion in hypothyroidism.
Topics: Adenoma; Adult; Cyproheptadine; Dopamine; Female; Humans; Hyperprolactinemia; Hypothyroidism; Metocl | 1992 |
Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Bromocriptine; Cyproheptadine; Diazepam; Female; Growth Horm | 1990 |
The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Aged; Bromocriptine; Cyproheptadine; Drug Therapy, Combination; Female; | 1989 |
The medical treatment of the hypersecreting pituitary gland.
Topics: Adenoma; Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Bromocriptine; Cyproheptadine; Ergoli | 1985 |
Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma.
Topics: Adenoma; Adult; Cushing Syndrome; Cyproheptadine; Female; Humans; Hydrocortisone; Pituitary Neoplasm | 1987 |